Stratec Se (SBS.DE) Stock Price

Stratec Se Price

XETRA·CLOSED
20.25EUR+0.15 (+0.74 %)
Market closed

Revenue has compounded at 7.6% per year over the past 18 years to 250.86 M EUR. Earnings per share have grown at 2.1% per year over the last 15 years. Stratec Se's net margin stands at -0.1%, down from 13.9% several years earlier. Stratec Se currently offers a dividend yield of about 2.96%. The dividend has grown at 3.7% per year over the past 19 years. Analysts set a median price target of 31.11 EUR, implying 53.6% above the current price. Of 11 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 23% above its 52-week low.

Stratec Se stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Stratec Se over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Stratec Se stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Stratec Se's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Stratec Se Stock Price History
DateStratec Se Price
8/5/202620.25 EUR
8/4/202620.10 EUR
7/31/202619.52 EUR
7/30/202620.30 EUR
7/29/202620.50 EUR
7/28/202620.15 EUR
7/27/202620.05 EUR
7/24/202619.70 EUR
7/23/202619.28 EUR
7/22/202619.20 EUR
7/21/202618.86 EUR
7/20/202618.98 EUR
7/17/202619.80 EUR
7/16/202620.00 EUR
7/15/202619.74 EUR
7/14/202619.00 EUR
7/13/202619.16 EUR
7/10/202619.00 EUR
7/9/202618.66 EUR
7/8/202617.74 EUR
7/7/202618.12 EUR
7/6/202618.46 EUR
7/3/202618.23 EUR
7/2/202618.00 EUR
7/1/202617.60 EUR
6/30/202616.80 EUR
6/29/202617.38 EUR
6/26/202617.70 EUR
6/25/202617.68 EUR
6/24/202617.44 EUR
6/23/202617.96 EUR
6/22/202618.16 EUR
6/19/202618.18 EUR
6/18/202618.22 EUR
6/17/202618.50 EUR
6/16/202618.26 EUR
6/15/202618.42 EUR
6/12/202617.80 EUR
6/11/202617.96 EUR
6/10/202618.06 EUR
6/9/202617.86 EUR
6/8/202617.44 EUR
6/5/202616.82 EUR
6/4/202616.88 EUR
6/3/202616.52 EUR
6/2/202616.78 EUR
6/1/202617.10 EUR
5/29/202617.68 EUR
5/28/202617.34 EUR
5/27/202616.66 EUR
5/26/202616.80 EUR
5/25/202616.92 EUR
5/22/202617.24 EUR
5/21/202617.04 EUR
5/20/202616.98 EUR
5/19/202616.88 EUR
5/18/202617.00 EUR
5/15/202616.76 EUR
5/14/202617.78 EUR
5/13/202617.36 EUR
5/12/202617.18 EUR
5/11/202617.60 EUR
5/8/202617.70 EUR
5/7/202617.78 EUR
5/6/202616.98 EUR
5/5/202616.76 EUR
5/4/202616.92 EUR
4/30/202617.60 EUR
4/29/202617.62 EUR
4/28/202618.00 EUR
4/27/202618.58 EUR
4/24/202618.40 EUR
4/23/202618.42 EUR
4/22/202619.00 EUR
4/21/202619.96 EUR
4/20/202619.64 EUR
4/17/202619.84 EUR
4/16/202618.48 EUR
4/15/202618.68 EUR
4/14/202618.90 EUR
4/13/202617.56 EUR
4/10/202617.76 EUR
4/9/202617.00 EUR
4/8/202617.36 EUR
4/7/202616.86 EUR
4/2/202617.76 EUR
4/1/202617.50 EUR
3/31/202617.10 EUR
3/30/202617.06 EUR
3/27/202617.28 EUR
3/26/202617.70 EUR
3/25/202619.20 EUR
3/24/202618.98 EUR
3/23/202619.06 EUR
3/20/202618.60 EUR
3/19/202618.92 EUR
3/18/202619.34 EUR
3/17/202619.12 EUR
3/16/202619.00 EUR
3/13/202618.84 EUR
3/12/202618.90 EUR
3/11/202618.76 EUR
3/10/202619.10 EUR
3/9/202619.12 EUR
3/6/202619.50 EUR
3/5/202619.28 EUR
3/4/202620.00 EUR
3/3/202620.00 EUR
3/2/202620.65 EUR
2/27/202621.10 EUR
2/26/202621.05 EUR
2/25/202620.70 EUR
2/24/202620.65 EUR
2/23/202620.25 EUR
2/20/202620.40 EUR
2/19/202620.10 EUR
2/18/202620.40 EUR
2/17/202620.90 EUR
2/16/202619.36 EUR
2/13/202619.92 EUR
2/12/202619.60 EUR
2/11/202620.45 EUR
2/10/202620.50 EUR
2/9/202620.80 EUR
2/6/202621.05 EUR
2/5/202620.90 EUR
2/4/202621.15 EUR
2/3/202621.50 EUR
2/2/202622.00 EUR
1/30/202622.35 EUR
1/29/202622.70 EUR
1/28/202622.60 EUR
1/27/202623.05 EUR
1/26/202623.35 EUR
1/23/202623.00 EUR
1/22/202622.90 EUR
1/21/202622.70 EUR
1/20/202621.90 EUR
1/19/202622.75 EUR
1/16/202623.85 EUR
1/15/202624.00 EUR
1/14/202623.85 EUR
1/13/202623.55 EUR
1/12/202623.40 EUR
1/9/202624.40 EUR
1/8/202622.50 EUR
1/7/202622.30 EUR
1/6/202622.65 EUR
1/5/202622.50 EUR
1/2/202622.10 EUR
12/30/202522.45 EUR
12/29/202522.50 EUR
12/23/202522.15 EUR
12/22/202522.45 EUR
12/19/202521.95 EUR
12/18/202522.15 EUR
12/17/202522.15 EUR
12/16/202522.15 EUR
12/15/202521.95 EUR
12/12/202521.95 EUR
12/11/202521.70 EUR
12/10/202522.00 EUR
12/9/202522.25 EUR
12/8/202522.70 EUR
12/5/202522.90 EUR
12/4/202522.85 EUR
12/3/202523.35 EUR
12/2/202523.35 EUR
12/1/202522.70 EUR
11/28/202522.50 EUR
11/27/202522.25 EUR
11/26/202522.10 EUR
11/25/202521.30 EUR
11/24/202520.85 EUR
11/21/202520.20 EUR
11/20/202519.98 EUR
11/19/202520.15 EUR
11/18/202520.30 EUR
11/17/202520.65 EUR
11/14/202521.35 EUR
11/13/202521.70 EUR
11/12/202521.70 EUR
11/11/202521.50 EUR
11/10/202520.65 EUR
11/7/202520.65 EUR
11/6/202520.65 EUR
11/5/202522.25 EUR
11/4/202522.25 EUR
11/3/202522.95 EUR
10/31/202523.50 EUR
10/30/202522.60 EUR
10/29/202524.90 EUR
10/28/202525.30 EUR
10/27/202525.75 EUR
10/24/202526.30 EUR
10/23/202526.70 EUR
10/22/202528.65 EUR
10/21/202528.85 EUR
10/20/202528.80 EUR
10/17/202527.30 EUR
10/16/202527.55 EUR
10/15/202528.00 EUR
10/14/202529.20 EUR
10/13/202528.70 EUR
10/10/202528.55 EUR
10/9/202530.25 EUR
10/8/202530.20 EUR
10/7/202532.00 EUR
10/6/202531.35 EUR
10/3/202531.35 EUR
10/2/202530.55 EUR
10/1/202530.35 EUR
9/30/202528.75 EUR
9/29/202528.75 EUR
9/26/202528.25 EUR
9/25/202528.65 EUR
9/24/202529.85 EUR
9/23/202530.65 EUR
9/22/202529.15 EUR
9/19/202529.15 EUR
9/18/202528.50 EUR
9/17/202527.60 EUR
9/16/202527.55 EUR
9/15/202527.50 EUR
9/12/202527.50 EUR
9/11/202527.50 EUR
9/10/202526.90 EUR
9/9/202526.40 EUR
9/8/202526.45 EUR
9/5/202526.20 EUR
9/4/202525.70 EUR
9/3/202525.60 EUR
9/2/202525.60 EUR
9/1/202526.40 EUR
8/29/202527.20 EUR
8/28/202527.50 EUR
8/27/202526.70 EUR
8/26/202525.60 EUR
8/25/202525.10 EUR
8/22/202525.85 EUR
8/21/202526.65 EUR
8/20/202526.25 EUR
8/19/202527.00 EUR
8/18/202525.85 EUR
8/15/202525.55 EUR
8/14/202526.20 EUR
8/13/202526.20 EUR
8/12/202526.55 EUR
8/11/202526.65 EUR
8/8/202527.40 EUR
8/7/202526.60 EUR
8/6/202526.60 EUR
Access this data via the Eulerpool API
Get Free API Key

Stratec Se Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
270.41 M EUR
28.12 M EUR
15.37 M EUR
Jan 1, 2024
257.62 M EUR
28.18 M EUR
16.02 M EUR
Jan 1, 2025
250.86 M EUR
8.59 M EUR
-242,000.00 EUR
Jan 1, 2026 (e)
263.66 M EUR
29.14 M EUR
16.95 M EUR
Jan 1, 2027 (e)
281.26 M EUR
31.08 M EUR
20.66 M EUR
Jan 1, 2028 (e)
299.41 M EUR
33.09 M EUR
24.39 M EUR
Jan 1, 2029 (e)
326.71 M EUR
36.11 M EUR
27.53 M EUR
Jan 1, 2030 (e)
351.17 M EUR
38.81 M EUR
31.49 M EUR

Stratec Se Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 6, 2026, 7:06 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
184.00209.00187.00221.00250.00287.00274.00270.00257.00250.00263.00281.00299.00326.00351.00363.00
26.0313.59-10.5318.1813.1214.80-4.53-1.46-4.81-2.725.206.846.419.037.673.42
33.1532.0625.6723.5327.2030.3128.8325.1929.5725.6025.6025.6025.6025.6025.6025.60
61.0067.0048.0052.0068.0087.0079.0068.0076.0064.0067.3371.9476.5483.4689.8692.93
24.0030.0015.0018.0033.0049.0041.0028.0028.008.0029.0031.0033.0036.0038.00–
13.0414.358.028.1413.2017.0714.9610.3710.893.2011.0311.0311.0411.0410.83–
19.0025.008.0014.0025.0039.0029.0015.0016.00–16.0020.0024.0027.0031.00–
-13.6431.58-68.0075.0078.5756.00-25.64-48.286.67––25.0020.0012.5014.81–
0.750.770.800.820.840.900.950.970.550.600.600.600.60–––
7.142.673.902.502.447.145.562.11-43.309.09––––––
12.0912.0912.0912.0912.0912.1912.1612.1612.1612.1612.1612.1612.1612.1612.1612.16
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Stratec Se generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Stratec Se retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Stratec Se's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Stratec Se has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Stratec Se's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Stratec Se stock margins

The Stratec Se margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Stratec Se. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Stratec Se.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
30.53 %
17.27 %
13.91 %
Jan 1, 2022
28.94 %
15.29 %
10.64 %
Jan 1, 2023
25.21 %
10.40 %
5.68 %
Jan 1, 2024
29.65 %
10.94 %
6.22 %
Jan 1, 2025
25.60 %
3.43 %
-0.10 %
Jan 1, 2026 (e)
25.60 %
11.05 %
6.43 %
Jan 1, 2027 (e)
25.60 %
11.05 %
7.34 %
Jan 1, 2028 (e)
25.60 %
11.05 %
8.14 %

Stratec Se Stock Revenue, EBIT, Earnings per Share

The Stratec Se earnings per share therefore indicates how much revenue Stratec Se has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
23.58 EUR
4.07 EUR
3.28 EUR
Jan 1, 2022
22.58 EUR
3.45 EUR
2.40 EUR
Jan 1, 2023
22.25 EUR
2.31 EUR
1.26 EUR
Jan 1, 2024
21.19 EUR
2.32 EUR
1.32 EUR
Jan 1, 2025
20.64 EUR
0.71 EUR
-0.02 EUR
Jan 1, 2026 (e)
21.69 EUR
2.40 EUR
1.39 EUR
Jan 1, 2027 (e)
23.14 EUR
2.56 EUR
1.70 EUR
Jan 1, 2028 (e)
24.63 EUR
2.72 EUR
2.01 EUR

Stratec Se business model & stock analysis

The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry.

Stratec Se SWOT Analysis

Strengths

Stratec SE holds a dominant position in the market, offering unique and innovative products/services that have gained significant traction among customers.

The company possesses strong technological expertise, allowing it to develop cutting-edge solutions that provide a competitive edge over rivals.

Stratec SE boasts an efficient supply chain management system, ensuring timely delivery of products to customers while minimizing costs.

The company invests heavily in research and development, continuously enhancing its product portfolio and offering innovative solutions to meet market demands.

Weaknesses

Stratec SE relies heavily on a few key customers for a significant portion of its revenue, making it vulnerable to potential loss if these customers switch to competitors.

The company's operations are primarily focused in specific geographic regions, limiting its exposure to global markets and potential opportunities.

Stratec SE's product portfolio is relatively narrow, which could limit its ability to cater to diverse customer requirements and adapt to changing market dynamics.

Opportunities

The global medical devices market is experiencing significant growth, presenting Stratec SE with opportunities to expand its customer base and increase revenues.

Advancements in technologies like artificial intelligence and Internet of Things offer Stratec SE the chance to develop innovative solutions and gain a competitive edge in the market.

The company can explore untapped markets and expand its operations internationally, diversifying its customer base and reducing dependency on specific regions or customers.

Threats

The medical devices market is highly competitive, with numerous players vying for market share, which could potentially erode Stratec SE's market position and profitability.

The industry is subject to stringent regulations and compliance requirements, and any changes in regulations could pose challenges for Stratec SE in terms of product development and market access.

Rapid technological advancements may render Stratec SE's existing products/services obsolete if the company fails to adapt and innovate accordingly.

Stratec Se Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Stratec Se historical P/E ratio, EBIT multiple, and P/S ratio

Stratec Se annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Stratec Se shares outstanding

The number of shares of Stratec Se was 12.16 M in 2025. This indicates how many shares Stratec Se is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
12.19 M Stocks
Jan 1, 2022
12.16 M Stocks
Jan 1, 2023
12.16 M Stocks
Jan 1, 2024
12.16 M Stocks
Jan 1, 2025
12.16 M Stocks
Jan 1, 2026 (e)
12.16 M Stocks
Jan 1, 2027 (e)
12.16 M Stocks
Jan 1, 2028 (e)
12.16 M Stocks

Stratec Se stock splits

In Stratec Se's history, there have been no stock splits.

Stratec Se Dividend History

22 years of dividend payments

YearAnnual DividendYoY ChangePayments
20250.60EUR↑ 9.1%1×
Jun 30, 20250.60EUR↑ 9.1%1/1
20240.55EUR↓ 43.3%1×
20230.97EUR↑ 2.1%1×
20220.95EUR↑ 5.6%1×
20210.90EUR↑ 7.1%1×
20200.84EUR↑ 2.4%1×
20190.82EUR↑ 2.5%1×
20180.80EUR↑ 3.9%1×
20170.77EUR↑ 2.7%1×
20160.75EUR↑ 7.1%1×

Stratec Se dividend history and estimates

In 2025, Stratec Se paid a dividend amounting to 0.60 EUR. Dividend means that Stratec Se distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
0.90 EUR
0.00 EUR
Jan 1, 2022
0.95 EUR
0.00 EUR
Jan 1, 2023
0.97 EUR
0.00 EUR
Jan 1, 2024
0.55 EUR
0.00 EUR
Jan 1, 2025
0.60 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
0.60 EUR
Jan 1, 2027 (e)
0.00 EUR
0.60 EUR
Jan 1, 2028 (e)
0.00 EUR
0.60 EUR

Stratec Se dividend payout ratio

In 2025, Stratec Se had a payout ratio of -3,013.86%. The payout ratio indicates the percentage of the company's profits that Stratec Se distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
27.45 %
Jan 1, 2022
39.54 %
Jan 1, 2023
76.72 %
Jan 1, 2024
41.73 %
Jan 1, 2025
-3,013.86 %
Jan 1, 2026 (e)
43.04 %
Jan 1, 2027 (e)
35.31 %
Jan 1, 2028 (e)
29.91 %

Current Stratec Se forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
72.73 % (8)
Hold
27.27 % (3)
Sell
0.00 % (0)
12M Price Target
31.11
Last Price
20.25
Currency
EUR
12M Return Potential
53.63 %
LTM Return
0 %

Stratec Se Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/5/20221.01EUR-78.15 MEUR-2022 Q1
11/11/20210.79EUR-72.47 MEUR-2021 Q3
3/31/20210.84EUR-76.13 MEUR-2020 Q4
11/5/20200.65EUR-60.90 MEUR-2020 Q3
8/13/20200.68EUR-66.69 MEUR-2020 Q2
5/14/20200.48EUR-57.85 MEUR-2020 Q1
4/2/20200.72EUR-60.90 MEUR-2019 Q4
8/15/20190.37EUR-56.84 MEUR-2019 Q2
5/24/20190.32EUR-48.16 MEUR-2019 Q1
4/19/20180.82EUR-67.09 MEUR-2017 Q4

EESG©

Eulerpool ESG Scorecard© for the Stratec Se stock

88/100
98
Environment
99
Social
66
Governance
E

Environment

20
Scope 1 - Direct Emissions639.1
Scope 2 - Indirect emissions from purchased energy1,376.7
Scope 3 - Indirect emissions within the value chain9,303.6
Total CO₂ emissions2,015.8
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees36.1
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Stratec Se shareholder structure

% Name
4.22958%
JPMorgan Asset Management U.K. Limited
JPMorgan Asset Management U.K. Limited
2.48597%
Janus Henderson Investors
Janus Henderson Investors
1.74857%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.57027%
Candriam Luxembourg S.A.
Candriam Luxembourg S.A.
1.48076%
UBS Fund Management (Switzerland) AG
UBS Fund Management (Switzerland) AG
1.06797%
Allianz Global Investors GmbH
Allianz Global Investors GmbH

Stratec Se Beneficial Ownership Filings (SEC 13D/G)

Free Float
62.4%
Float Shares
-
Shares Outstanding
-

Stratec Se Executives and Management Board

9 members · avg. age 60 · 11 % women

MW

Mr. Marcus Wolfinger (57)

Chairman of the Management Board, Chief Executive Officer

900,000.00 EUR

Management

OA

Mr. Oliver Albrecht

Interim Chief Financial Officer, Member of the Management Board

–
JK

Mr. Jan Keppeler

Head of Investor Relations, Sustainability and Corporate Communications · since 2025

–

Board of Directors

CV

Dr. Claus Vielsack (57)

Member of the Management Board, Director - Product Development

653,000.00 EUR
GB

Dr. Georg Bauer (52)

Director - Sales, Member of the Management Board

451,000.00 EUR
PH

Prof. Dr. Georg Heni (67)

Independent Chairman of the Supervisory Board · since 2022

96,000.00 EUR
FH

Dr. Frank Hiller (59)

Independent Deputy Chairman of the Supervisory Board · since 2019

76,000.00 EUR
PG

Dr. Patricia Geller (58)

Independent Member of the Supervisory Board

56,000.00 EUR
RV

Dr. Rolf Vornhagen (72)

Independent Member of the Supervisory Board

51,000.00 EUR

Stratec Se Supply Chain

Stratec Se Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
5 companies
#NameTrend
1
DiaSorin SpA
Supplier·Customer·Health Care Equipment & Supplies·IT
0.67
0.88
0.88
0.93
0.92
0.69
2
Hologic
Supplier·Customer·Health Care Equipment & Supplies·US
0.76
-0.28
0.28
0.21
0.35
0.52
#NameTrend
1
Quanterix
Supplier·Customer·Life Sciences Tools & Services·US
0.51
0.80
0.79
0.82
0.63
—
2
Medicon Hellas
Customer·Health Care Equipment & Supplies·GR
-0.27
0.72
0.51
0.16
-0.43
—
3
Quotient
Supplier·Customer·Health Care Equipment & Supplies·CH
-0.36
0.71
0.66
0.79
0.57
-0.13

Frequently asked questions about Stratec Se

The business model of Stratec SE revolves around providing innovative solutions and services to the diagnostics industry. As a leading global technology partner, Stratec SE specializes in developing and producing automated analyzer systems that enable fast, reliable, and cost-effective diagnostics. By focusing on instrument and assay integration, Stratec SE helps its customers streamline their processes and improve laboratory efficiency. The company's comprehensive portfolio covers a wide range of applications, including clinical diagnostics, blood banking, and pharmaceutical quality control. With its expertise and cutting-edge technologies, Stratec SE aims to drive advancements in diagnostics and contribute to improving patient care worldwide.

Stratec SE is primarily active in the life sciences and medical technology industries.

The main competitors of Stratec SE in the market include companies like Thermo Fisher Scientific, Becton, Dickinson and Company, PerkinElmer Inc., and Bio-Rad Laboratories.

Stratec SE, a leading global supplier of laboratory automation and diagnostic solutions, has a rich history and background. Established in 1979 in Birkenfeld, Germany, the company has grown from a small start-up to a renowned player in the life science industry. Stratec SE specializes in developing innovative technologies and devices that enable faster and more efficient diagnostics and research processes. With a strong focus on customer satisfaction and strategic partnerships, Stratec SE has expanded its presence worldwide. Today, the company serves a diverse range of customers, including pharmaceutical firms, medical device manufacturers, and research institutions. Stratec SE's dedication to technological advancement and commitment to quality make it a trusted name in the industry.

Stratec SE, a renowned stock company, has accomplished several notable milestones throughout its journey. One prominent achievement is the successful development of innovative laboratory and diagnostic solutions for the global healthcare industry. Stratec SE has also gained recognition for its strategic partnerships and collaborations, fostering growth and expanding its market presence. Moreover, the company has consistently delivered strong financial performance, achieving sustainable revenue growth and enhancing shareholder value. Stratec SE's commitment to continuous innovation, dedication to quality, and focus on customer satisfaction has positioned it as a key player in the industry, ensuring its ongoing success and reputation as a trusted stock investment.

Stratec SE is primarily present in various countries and regions. As a global company, its presence extends across Europe, North America, and Asia. Stratec SE operates in countries such as Germany, Switzerland, the United States, China, and Japan, among others. With its strong international footprint, Stratec SE has established itself as a leading provider of innovative solutions in the fields of in-vitro diagnostics and life sciences.

Stratec SE represents a strong set of values and corporate philosophy. With a focus on innovation and quality, the company aims to provide cutting-edge solutions in the field of automation and instrumentation for medical diagnostics. Stratec SE puts a strong emphasis on customer satisfaction and long-term partnerships, striving for continuous improvement and excellence. By fostering a culture of collaboration, integrity, and professionalism, the company aims to drive sustainable growth and deliver value to its shareholders. Stratec SE's commitment to delivering high-performance products and services, coupled with its dedication to corporate responsibility, sets it apart in the industry.

Analysts currently set an average price target of 34.95 EUR for the Stratec Se stock (median: 31.11 EUR), implying +72.6 % versus the latest price. The consensus is based on 11 analyst ratings.

Stratec Se Analyst Price Targets 2026

11 analysts currently rate the Stratec Se stock: 8 recommend buying, 3 holding and 0 selling. For 2026, analysts expect Stratec Se to generate revenue of 263.66 M EUR and earnings per share of 1.39 EUR.

Stratec Se Analyst Price Targets 2026

The Stratec Se share (SBS.DE) is listed on 8 stock exchanges, including: XETRA (SBS.DE), Frankfurt (SBS.F), München (SBS.MU), Düsseldorf (SBS.DU), Hamburg (SBS.HM), London (0RAR.L), London (0RAR.L), SIX (Zürich) (SBS.SW).

Stratec SE is a leading provider of automation solutions for the diagnostic and analytic industry. The company offers a wide portfolio of products and services that are part of its core business. Stratec operates in two business segments: instrumentation and diagnostics. (Instrumentation) Stratec offers a wide range of automation solutions, including the development, production, and distribution of equipment and systems for automated sample processing in clinical laboratories, as well as industrial automation for the production of medical devices and system solutions in the fields of life science and diagnostics. The company is a market leader in immunology and hematology and is also present in other segments such as microbiology and molecular biology. (Diagnostics) The diagnostic business segment provides specialized immunological and molecular tests for a variety of medical applications in the in vitro diagnostic (IVD) market. The company focuses on immuno-oncology, gastroenterology, infectious diseases, and cardiovascular diseases. Stratec offers comprehensive development, production, quality control, life cycle, and market release management services. The company emphasizes close collaboration with its customers to develop innovative solutions of the highest quality that meet the highest requirements for precision, reliability, and scalability. Stratec has demonstrated its resilience, successfully navigating through the COVID-19 pandemic in 2020. The company has proven to be crisis-resistant and has guided its employees through the crisis. With a strong global presence and industry-specific expertise, Stratec is able to continuously meet customer requirements. The company has established its business in the United Kingdom and the United States and plans to expand into other countries, primarily in Asia. Wherever Stratec operates, it emphasizes open and collaborative partnerships with customers and other stakeholders. Overall, Stratec SE is a company that impresses with its comprehensive automation solutions for the diagnostic and analytic industry. The instrumentation business segment covers multiple areas of medicine, while the diagnostics business segment specializes in the development and production of diagnostic solutions. Together, both segments enable optimal collaboration with customers and comprehensive expertise in the industry. The company is capable of addressing both customer needs and industry requirements as a whole.

The expected revenue of Stratec Se is 263.66 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Stratec Se is 16.95 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Stratec Se is currently 14.53. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Stratec Se stock.

The price-to-sales ratio (P/S) of Stratec Se is currently 0.93. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Stratec Se stock.

The Eulerpool Quality Score for Stratec Se is 2/10.

The ISIN of Stratec Se is DE000STRA555. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Stratec Se is STRA55. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Stratec Se is SBS.DE. The ticker symbol is used to trade Stratec Se shares on the stock exchange.

Over the past 12 months, Stratec Se paid a dividend of 0.60 EUR . This corresponds to a dividend yield of about 2.96 %. For the coming 12 months, Stratec Se is expected to pay a dividend of 0.60 EUR.

The current dividend yield of Stratec Se is 2.96 %.

Stratec Se pays a dividend, distributed in the months of , , , .

Stratec Se paid dividends every year for the past 22 years.

For the upcoming 12 months, dividends amounting to 0.60 EUR are expected. This corresponds to a dividend yield of 2.99 %.

Stratec Se is assigned to the 'Health' sector.

To receive the latest dividend of Stratec Se from amounting to 0.6 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Stratec Se distributed 0.55 EUR as dividends.

The dividends of Stratec Se are distributed in EUR.

All fundamentals and in-depth analysis of Stratec Se

Our stock analysis for Stratec Se stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Stratec Se. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Stratec Se Stock
Stratec Se Revenue→
Stratec Se Stock
Stratec Se Net Income→
Stratec Se Stock
Stratec Se P/E→
Stratec Se Stock
Stratec Se P/S→
Stratec Se Stock
Stratec Se EBIT→
Stratec Se Stock
Stratec Se Dividend→
Stratec Se Stock
Stratec Se Directors Dealings→
Stratec Se Stock
Stratec Se Stocks→
Stratec Se Stock
Stratec Se Market capitalization→
Stratec Se Stock
Stratec Se Debt→
Stratec Se Stock
Stratec Se Liabilities→
Stratec Se Stock
Stratec Se Equity→
Stratec Se Stock
Stratec Se AAQS→
Stratec Se Stock
Stratec Se Employees→
Stratec Se Stock
Stratec Se ROE→
Stratec Se Stock
Stratec Se ROA→
Stratec Se Stock
Stratec Se ROCE→
Stratec Se Stock
Stratec Se News→
Stratec Se Stock
Stratec Se Analyst Price Targets→

Health Stocks

Strategic Partners A/SStrata Skin SciencesStraumann HoldingStoke TherapeuticsStreamexStimCell EnegeticsStrides Pharma ScienceStilleStromacelStevanato Group SpAStructure Therapeutics Inc. American Depositary SharesSTERIS plcAll Stocks A–Z →